Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Bile salts and cholestasis

Maillette de Buy Wenniger, Lucas, Beuers, Ulrich·2010·Digestive and Liver Disease

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dld.2010.03.015

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 167

  1. Hofmann, 2006, How bile acids confer gut mucosal protection against bacteria, Proc Natl Acad Sci USA, 103, 4333, 10.1073/pnas.0600780103 · DOI · Paper page
  2. Begley, 2005, The interaction between bacteria and bile, FEMS Microbiol Rev, 29, 625, 10.1016/j.femsre.2004.09.003 · DOI · Paper page
  3. Hofmann, 2008, Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics, Cell Mol Life Sci, 65, 2461, 10.1007/s00018-008-7568-6 · DOI · Paper page
  4. Zollner, 2009, Nuclear receptors as therapeutic targets in cholestatic liver diseases, Br J Pharmacol, 156, 7, 10.1111/j.1476-5381.2008.00030.x · DOI · Paper page
  5. Schmucker, 1990, Hepatic injury induced by bile salts: correlation between biochemical and morphological events, Hepatology, 12, 1216, 10.1002/hep.1840120523 · DOI · Paper page
  6. Hofmann, 1984, Physicochemical properties of bile acids and their relationship to biological properties: an overview of the problem, J Lipid Res, 25, 1477, 10.1016/S0022-2275(20)34421-7 · DOI · Paper page
  7. Griffiths, 2009, Bile acids: analysis in biological fluids and tissues, J Lipid Res, 10.1194/jlr.R001941 · DOI
  8. Hofmann, 2009, Bile salts of vertebrates: structural variation and possible evolutionary significance, J Lipid Res
  9. Monte, 2009, Bile acids: chemistry, physiology, and pathophysiology, World J Gastroenterol, 15, 804, 10.3748/wjg.15.804 · DOI · Paper page
  10. Perez, 2009, Bile-acid-induced cell injury and protection, World J Gastroenterol, 15, 1677, 10.3748/wjg.15.1677 · DOI · Paper page
  11. Roda, 1990, Physicochemical and biological properties of natural and synthetic C-22 and C-23 hydroxylated bile acids, J Lipid Res, 31, 289, 10.1016/S0022-2275(20)43214-6 · DOI
  12. Hofmann, 1992, Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions, J Lipid Res, 33, 617, 10.1016/S0022-2275(20)41426-9 · DOI · Paper page
  13. Hagey, 1993, Ursodeoxycholic acid in the Ursidae: biliary bile acids of bears, pandas, and related carnivores, J Lipid Res, 34, 1911, 10.1016/S0022-2275(20)35109-9 · DOI
  14. Sola, 2006, Plasma levels of ursodeoxycholic acid in black bears, Ursus americanus: seasonal changes, Comp Biochem Physiol C Toxicol Pharmacol, 143, 204, 10.1016/j.cbpc.2006.02.002 · DOI
  15. Poupon, 1993, Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy, Hepatology, 17, 599, 10.1002/hep.1840170412 · DOI
  16. Reddy, 1998, Faecal pH, bile acid and sterol concentrations in premenopausal Indian and white vegetarians compared with white omnivores, Br J Nutr, 79, 495, 10.1079/BJN19980087 · DOI
  17. van Faassen, 1993, Bile acids and pH values in total feces and in fecal water from habitually omnivorous and vegetarian subjects, Am J Clin Nutr, 58, 917, 10.1093/ajcn/58.6.917 · DOI
  18. Bisschop, 2004, Low-fat, high-carbohydrate and high-fat, low-carbohydrate diets decrease primary bile acid synthesis in humans, Am J Clin Nutr, 79, 570, 10.1093/ajcn/79.4.570 · DOI
  19. Asakura, 2008, Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis?, J Gastroenterol Hepatol, 23, 1794, 10.1111/j.1440-1746.2008.05681.x · DOI
  20. Meier, 2002, Bile salt transporters, Annu Rev Physiol, 64, 635, 10.1146/annurev.physiol.64.082201.100300 · DOI · Paper page
  21. Strautnieks, 1998, A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis, Nat Genet, 20, 233, 10.1038/3034 · DOI · Paper page
  22. Duarte, 2009, Identification of metabolites in human hepatic bile using 800MHz 1H NMR spectroscopy, HPLC-NMR/MS and UPLC–MS. Mol Biosyst, 5, 180, 10.1039/B814426E · DOI
  23. Chari, 1996, Adenosine nucleotides in bile, Am J Physiol, 270, G246
  24. Chen, 2007, Two-dimensional electrophoresis for comparative proteomic analysis of human bile, Hepatobiliary Pancreat Dis Int, 6, 402
  25. Farina, 2009, Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer, J Proteome Res, 8, 159, 10.1021/pr8004925 · DOI
  26. Kristiansen, 2004, A proteomic analysis of human bile, Mol Cell Proteomics, 3, 715, 10.1074/mcp.M400015-MCP200 · DOI · Paper page
  27. Glickerman, 1997, The gallbladder also secretes, Dig Dis Sci, 42, 489, 10.1023/A:1018826521600 · doi:10.1023/a:1018826521600
  28. von Ritter, 1997, Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9, Anticancer Res, 17, 2931
  29. Hofmann, 2009, The enterohepatic circulation of bile acids in mammals: form and functions, Front Biosci, 14, 2584, 10.2741/3399 · DOI · Paper page
  30. Hruz, 2006, Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis, Gut, 55, 395, 10.1136/gut.2005.067389 · DOI
  31. Ballatori, 2008, Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver, Am J Physiol Gastrointest Liver Physiol, 295, G179, 10.1152/ajpgi.90319.2008 · DOI
  32. Ballatori, 2009, OST alpha-OST beta: a key membrane transporter of bile acids and conjugated steroids, Front Biosci, 14, 2829, 10.2741/3416 · DOI
  33. Ma, 2009, Circadian dysregulation disrupts bile acid homeostasis, PLoS One, 4, e6843, 10.1371/journal.pone.0006843 · DOI
  34. Alpini, 2005, Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats, Hepatology, 41, 1037, 10.1002/hep.20653 · DOI
  35. Xia, 2006, Bile acid interactions with cholangiocytes, World J Gastroenterol, 12, 3553, 10.3748/wjg.v12.i22.3553 · DOI · Paper page
  36. Fickert, 2006, 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice, Gastroenterology, 130, 465, 10.1053/j.gastro.2005.10.018 · DOI · Paper page
  37. Glaser, 2009, Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis, Hepatology, 49, 1795, 10.1002/hep.22969 · DOI
  38. Shindo, 1998, Omeprazole induces altered bile acid metabolism, Gut, 42, 266, 10.1136/gut.42.2.266 · DOI
  39. Beuers, 1991, Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man, J Hepatol, 13, 97, 10.1016/0168-8278(91)90870-H · DOI
  40. Toda, 2009, Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora, Drug Metab Pharmacokinet, 24, 201, 10.2133/dmpk.24.201 · DOI
  41. Lepercq, 2005, Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria, Br J Nutr, 93, 457, 10.1079/BJN20041386 · DOI
  42. Handschin, 2005, Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR, Arch Biochem Biophys, 433, 387, 10.1016/j.abb.2004.08.030 · DOI · Paper page
  43. Tietz, 2003, Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes, J Biol Chem, 278, 20413, 10.1074/jbc.M302108200 · DOI
  44. Lam, 2009, Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP), Am J Physiol Gastrointest Liver Physiol, 297, G90, 10.1152/ajpgi.00094.2009 · DOI
  45. Gunnarsdottir, 2003, Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension, Am J Gastroenterol, 98, 1362, 10.1111/j.1572-0241.2003.07475.x · doi:10.1111/j.1572-0241.2003.07475.x · Paper page
  46. Slocum, 1992, Absence of intestinal bile promotes bacterial translocation, Am Surg, 58, 305
  47. D’Aldebert, 2009, Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium, Gastroenterology, 136, 1435, 10.1053/j.gastro.2008.12.040 · DOI · Paper page
  48. Stange, 2009, For bugs in bile: the times they are a-changin, Gastroenterology, 136, 1164, 10.1053/j.gastro.2009.02.020 · DOI
  49. Ding, 1993, The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats, Eur Surg Res, 25, 11, 10.1159/000129252 · DOI · Paper page
  50. Beuers, 1997, Effects of bile acids on hepatocellular signaling and secretion, Yale J Biol Med, 70, 341
  51. Anwer, 2004, Cellular regulation of hepatic bile acid transport in health and cholestasis, Hepatology, 39, 581, 10.1002/hep.20090 · DOI
  52. Zollner, 2006, Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations, Mol Pharm, 3, 231, 10.1021/mp060010s · DOI · Paper page
  53. Anwer, 1988, Hepatotoxic bile acids increase cytosolic Ca++ activity of isolated rat hepatocytes, Hepatology, 8, 887, 10.1002/hep.1840080430 · DOI
  54. Beuers, 1993, Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes, Gastroenterology, 104, 604, 10.1016/0016-5085(93)90433-D · DOI
  55. Beuers, 1996, Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes, Gastroenterology, 110, 1553, 10.1053/gast.1996.v110.pm8613063 · DOI
  56. Bouscarel, 1999, Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers, Gastroenterology, 117, 433, 10.1053/gast.1999.0029900433 · DOI
  57. Rao, 1997, Activation of protein kinase C alpha and delta by bile acids: correlation with bile acid structure and diacylglycerol formation, J Lipid Res, 38, 2446, 10.1016/S0022-2275(20)30029-8 · DOI
  58. Beuers, 1993, Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis, J Clin Invest, 92, 2984, 10.1172/JCI116921 · DOI · Paper page
  59. Misra, 1998, The role of phosphoinositide 3-kinase in taurocholate-induced trafficking of ATP-dependent canalicular transporters in rat liver, J Biol Chem, 273, 26638, 10.1074/jbc.273.41.26638 · DOI
  60. Misra, 1999, Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles, Proc Natl Acad Sci USA, 96, 5814, 10.1073/pnas.96.10.5814 · DOI
  61. Beuers, 2003, Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets, J Biol Chem, 278, 17810, 10.1074/jbc.M209898200 · DOI
  62. Haussinger, 2003, Involvement of integrins and Src in tauroursodeoxycholate-induced and swelling-induced choleresis, Gastroenterology, 124, 1476, 10.1016/S0016-5085(03)00274-9 · DOI
  63. Dent, 2005, Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes, Hepatology, 42, 1291, 10.1002/hep.20942 · DOI
  64. Nguyen, 2008, Bile acids and signal transduction: role in glucose homeostasis, Cell Signal, 20, 2180, 10.1016/j.cellsig.2008.06.014 · DOI · Paper page
  65. Lefebvre, 2009, Role of bile acids and bile acid receptors in metabolic regulation, Physiol Rev, 89, 147, 10.1152/physrev.00010.2008 · DOI · Paper page
  66. Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice, Proc Natl Acad Sci USA, 103, 1006, 10.1073/pnas.0506982103 · DOI · Paper page
  67. Houten, 2006, Endocrine functions of bile acids, EMBO J, 25, 1419, 10.1038/sj.emboj.7601049 · DOI · Paper page
  68. Keitel, 2008, Endocrine and paracrine role of bile acids, World J Gastroenterol, 14, 5620, 10.3748/wjg.14.5620 · DOI
  69. Ikemoto, 1997, Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease, Am J Physiol, 273, E37
  70. Ishizawa, 2008, Lithocholic acid derivatives act as selective vitamin D receptor modulators without inducing hypercalcemia, J Lipid Res, 49, 763, 10.1194/jlr.M700293-JLR200 · DOI
  71. Yamazaki, 2001, Bile acids induce eosinophil degranulation by two different mechanisms, Hepatology, 33, 582, 10.1053/jhep.2001.22168 · doi:10.1053/jhep.2001.22168
  72. Bergamini, 1997, Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells, Hepatology, 25, 927, 10.1002/hep.510250423 · DOI
  73. Oumi, 2000, A scanning electron microscope study on the effects of different bile salts on the epithelial lining of jejunal mucosa, Med Electron Microsc, 33, 11, 10.1007/s007950000002 · DOI
  74. Benedetti, 1997, Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver, Hepatology, 26, 9, 10.1002/hep.510260102 · DOI
  75. Hofmann, 1999, The continuing importance of bile acids in liver and intestinal disease, Arch Intern Med, 159, 2647, 10.1001/archinte.159.22.2647 · DOI · Paper page
  76. Palmeira, 2004, Mitochondrially-mediated toxicity of bile acids, Toxicology, 203, 1, 10.1016/j.tox.2004.06.001 · DOI · Paper page
  77. Sokol, 1998, Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat, Gastroenterology, 114, 164, 10.1016/S0016-5085(98)70644-4 · DOI · Paper page
  78. Schubert, 1988, Structural changes in vesicle membranes and mixed micelles of various lipid compositions after binding of different bile salts, Biochemistry, 27, 8787, 10.1021/bi00424a015 · DOI
  79. Lemasters, 1998, The mitochondrial permeability transition: from biochemical curiosity to pathophysiological mechanism, Gastroenterology, 115, 783, 10.1016/S0016-5085(98)70160-X · DOI
  80. Lemasters, 1998, The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy, Biochim Biophys Acta, 1366, 177, 10.1016/S0005-2728(98)00112-1 · DOI · Paper page
  81. Lemasters, 2009, Mitochondrial calcium and the permeability transition in cell death, Biochim Biophys Acta, 1787, 1395, 10.1016/j.bbabio.2009.06.009 · DOI · Paper page
  82. Sokol, 2005, Human hepatic mitochondria generate reactive oxygen species and undergo the permeability transition in response to hydrophobic bile acids, J Pediatr Gastroenterol Nutr, 41, 235, 10.1097/01.MPG.0000170600.80640.88 · DOI
  83. Rolo, 2003, Mitochondrially mediated synergistic cell killing by bile acids, Biochim Biophys Acta, 1637, 127, 10.1016/S0925-4439(02)00224-7 · DOI
  84. Sokol, 1995, Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids, Gastroenterology, 109, 1249, 10.1016/0016-5085(95)90585-5 · DOI · Paper page
  85. Gumpricht, 2008, Resistance of young rat hepatic mitochondria to bile acid-induced permeability transition: potential role of alpha-tocopherol, Pediatr Res, 64, 498, 10.1203/PDR.0b013e3181841ee1 · DOI
  86. Yerushalmi, 2001, Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition, Hepatology, 33, 616, 10.1053/jhep.2001.22702 · DOI · Paper page
  87. Prince, 2003, Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial, Aliment Pharmacol Ther, 17, 137, 10.1046/j.1365-2036.2003.01398.x · DOI
  88. Reinehr, 2003, Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation, Gastroenterology, 125, 839, 10.1016/S0016-5085(03)01055-2 · DOI
  89. Reinehr, 2005, Bile salt-induced apoptosis involves NADPH oxidase isoform activation, Gastroenterology, 129, 2009, 10.1053/j.gastro.2005.09.023 · DOI
  90. Rust, 2009, Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent, J Biol Chem, 284, 2908, 10.1074/jbc.M804585200 · DOI
  91. Kim, 2008, Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities, Nat Rev Drug Discov, 7, 1013, 10.1038/nrd2755 · DOI · Paper page
  92. Kaplowitz, 2007, Endoplasmic reticulum stress and liver injury, Semin Liver Dis, 27, 367, 10.1055/s-2007-991513 · DOI
  93. Iizaka, 2007, Interaction between caspase-8 activation and endoplasmic reticulum stress in glycochenodeoxycholic acid-induced apoptotic HepG2 cells, Toxicology, 241, 146, 10.1016/j.tox.2007.08.095 · DOI
  94. Hitomi, 2004, Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Abeta-induced cell death, J Cell Biol, 165, 347, 10.1083/jcb.200310015 · DOI · Paper page
  95. Bochkis, 2008, Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress, Nat Med, 14, 828, 10.1038/nm.1853 · DOI · Paper page
  96. Kitani, 1985, Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat, Am J Physiol, 248, G407
  97. Wimmer, 2008, Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver, Gut, 57, 1448, 10.1136/gut.2007.140871 · DOI
  98. Marzioni, 2006, Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts, Am J Pathol, 168, 398, 10.2353/ajpath.2006.050126 · DOI
  99. Lazaridis, 2001, Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’, J Hepatol, 35, 134, 10.1016/S0168-8278(01)00092-7 · DOI · Paper page
  100. Beuers, 1998, Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications, Hepatology, 28, 1449, 10.1002/hep.510280601 · DOI · Paper page
  101. Dombrowski, 2006, Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver, Lab Invest, 86, 166, 10.1038/labinvest.3700371 · DOI
  102. Beuers, 2001, Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver, Hepatology, 33, 1206, 10.1053/jhep.2001.24034 · DOI · Paper page
  103. Fiorotto, 2007, Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion, Gastroenterology, 133, 1603, 10.1053/j.gastro.2007.08.071 · DOI
  104. Minagawa, 2007, Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile, Gastroenterology, 133, 1592, 10.1053/j.gastro.2007.08.020 · DOI
  105. Nathanson, 2001, Stimulation of ATP secretion in the liver by therapeutic bile acids, Biochem J, 358, 1, 10.1042/0264-6021:3580001 · DOI
  106. Rodrigues, 1998, A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation, J Clin Invest, 101, 2790, 10.1172/JCI1325 · DOI · Paper page
  107. Serviddio, 2004, Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress, Hepatology, 39, 711, 10.1002/hep.20101 · DOI
  108. Rodrigues, 2001, The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent, Expert Opin Investig Drugs, 10, 1243, 10.1517/13543784.10.7.1243 · DOI
  109. Mitsuyoshi, 1999, Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants, Biochem Biophys Res Commun, 263, 537, 10.1006/bbrc.1999.1403 · DOI · Paper page
  110. Heathcote, 1994, The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis, Hepatology, 19, 1149, 10.1002/hep.1840190512 · DOI · Paper page
  111. Lindor, 1994, Ursodeoxycholic acid in the treatment of primary biliary cirrhosis, Gastroenterology, 106, 1284, 10.1016/0016-5085(94)90021-3 · DOI · Paper page
  112. Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis, Hepatology, 22, 759
  113. Pares, 2000, Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver, J Hepatol, 32, 561, 10.1016/S0168-8278(00)80216-0 · DOI · Paper page
  114. Shi, 2006, Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials, Am J Gastroenterol, 101, 1529, 10.1111/j.1572-0241.2006.00634.x · DOI
  115. Lindor, 2000, Ursodeoxycholic acid for primary biliary cirrhosis, Lancet, 355, 657, 10.1016/S0140-6736(05)72401-6 · DOI
  116. Corpechot, 2005, The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis, Gastroenterology, 128, 297, 10.1053/j.gastro.2004.11.009 · DOI · Paper page
  117. Kuiper, 2009, Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid, Gastroenterology, 136, 1281, 10.1053/j.gastro.2009.01.003 · DOI · Paper page
  118. O’Brien, 1991, Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study, Hepatology, 14, 838, 10.1002/hep.1840140516 · DOI · Paper page
  119. Beuers, 1992, Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial, Hepatology, 16, 707, 10.1002/hep.1840160315 · DOI · Paper page
  120. Stiehl, 1994, Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis, Scand J Gastroenterol Suppl, 204, 59, 10.3109/00365529409103626 · DOI
  121. Rost, 2004, Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis, Hepatology, 40, 693, 10.1002/hep.20370 · DOI
  122. Mitchell, 2001, A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis, Gastroenterology, 121, 900, 10.1053/gast.2001.27965 · DOI · Paper page
  123. Harnois, 2001, High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis, Am J Gastroenterol, 96, 1558, 10.1111/j.1572-0241.2001.03777.x · DOI · Paper page
  124. Lindor, 2009, High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis, Hepatology, 50, 808, 10.1002/hep.23082 · DOI · Paper page
  125. Lindor, 2008, Randomized, double-blind controlled trial of high-dose ursodeoxycholic acid for primary sclerosing cholangitis, Hepatology, 48, 378A
  126. Bergquist, 2002, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis, J Hepatol, 36, 321, 10.1016/S0168-8278(01)00288-4 · DOI · Paper page
  127. Tung, 2001, Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis, Ann Intern Med, 134, 89, 10.7326/0003-4819-134-2-200101160-00008 · DOI · Paper page
  128. Wolf, 2005, The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis, Aliment Pharmacol Ther, 22, 783, 10.1111/j.1365-2036.2005.02650.x · DOI
  129. Pardi, 2003, Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis, Gastroenterology, 124, 889, 10.1053/gast.2003.50156 · DOI · Paper page
  130. Rudolph, 2007, The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid, Eur J Gastroenterol Hepatol, 19, 487, 10.1097/MEG.0b013e3281108068 · DOI
  131. Lazaridis, 2006, Primary sclerosing cholangitis and cholangiocarcinoma, Semin Liver Dis, 26, 42, 10.1055/s-2006-933562 · DOI
  132. Brandsaeter, 2004, Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy, J Hepatol, 40, 815, 10.1016/j.jhep.2004.01.002 · DOI · Paper page
  133. Palma, 1997, Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo, J Hepatol, 27, 1022, 10.1016/S0168-8278(97)80146-8 · DOI · Paper page
  134. Williamson, 2004, Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group, BJOG, 111, 676, 10.1111/j.1471-0528.2004.00167.x · DOI
  135. Roncaglia, 2004, A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis, BJOG, 111, 17, 10.1046/j.1471-0528.2003.00029.x · DOI
  136. Glantz, 2005, Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid, Hepatology, 42, 1399, 10.1002/hep.20952 · DOI · Paper page
  137. Kondrackiene, 2005, Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy, Gastroenterology, 129, 894, 10.1053/j.gastro.2005.06.019 · DOI · Paper page
  138. Binder, 2006, Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy, J Perinat Med, 34, 383, 10.1515/JPM.2006.077 · DOI
  139. Glantz, 2008, Intrahepatic cholestasis of pregnancy: amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine, Hepatology, 47, 544, 10.1002/hep.21987 · DOI
  140. Colombo, 1996, Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis, Hepatology, 23, 1484, 10.1002/hep.510230627 · DOI · Paper page
  141. van de Meeberg, 1997, Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up, Scand J Gastroenterol, 32, 369, 10.3109/00365529709007686 · DOI
  142. Lindblad, 1998, A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease, Hepatology, 27, 166, 10.1002/hep.510270126 · DOI · Paper page
  143. Davit-Spraul, 2009, Progressive familial intrahepatic cholestasis, Orphanet J Rare Dis, 4, 1, 10.1186/1750-1172-4-1 · DOI · Paper page
  144. Jacquemin, 2001, The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood, Gastroenterology, 120, 1448, 10.1053/gast.2001.23984 · DOI · Paper page
  145. Nathwani, 2006, Drug hepatotoxicity, Clin Liver Dis, 10, 207, 10.1016/j.cld.2006.05.009 · DOI
  146. Essell, 1998, Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, 128, 975, 10.7326/0003-4819-128-12_Part_1-199806150-00002 · DOI · Paper page
  147. Ohashi, 2000, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation, Am J Hematol, 64, 32, 10.1002/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N · doi:10.1002/(sici)1096-8652(200005)64:1<32::aid-ajh6>3.0.co;2-n
  148. Ruutu, 2002, Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation, Blood, 100, 1977, 10.1182/blood-2001-12-0159 · DOI · Paper page
  149. Tay, 2007, Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 13, 206, 10.1016/j.bbmt.2006.09.012 · DOI
  150. DeLeve, 2009, Vascular disorders of the liver, Hepatology, 49, 1729, 10.1002/hep.22772 · DOI · Paper page
  151. 2009, European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B, J Hepatol, 50, 227, 10.1016/j.jhep.2008.10.001 · DOI · Paper page
  152. Ghany, 2009, Diagnosis, management, and treatment of hepatitis C: an update, Hepatology, 49, 1335, 10.1002/hep.22759 · DOI · Paper page
  153. Pelletier, 2003, A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice, Hepatology, 37, 887, 10.1053/jhep.2003.50118 · DOI
  154. Mancinelli, 2009, Taurocholate feeding to bile duct ligated rats prevents caffeic acid-induced bile duct damage by changes in cholangiocyte VEGF expression, Exp Biol Med (Maywood), 234, 462, 10.3181/0808-RM-255 · DOI
  155. Ueno, 2007, Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway, Exp Biol Med (Maywood), 232, 942
  156. Marzioni, 2007, Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver, Liver Int, 27, 558, 10.1111/j.1478-3231.2007.01443.x · DOI
  157. Sundaram, 2008, Mechanisms of disease: inborn errors of bile acid synthesis, Nat Clin Pract Gastroenterol Hepatol, 5, 456, 10.1038/ncpgasthep1179 · DOI · Paper page
  158. Oude Elferink, 2006, Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases, Gastroenterology, 130, 908, 10.1053/j.gastro.2005.08.052 · DOI · Paper page
  159. Heubi, 2007, Inborn errors of bile acid metabolism, Semin Liver Dis, 27, 282, 10.1055/s-2007-985073 · DOI
  160. Gonzales, 2009, Oral cholic acid for hereditary defects of primary bile acid synthesis: a safe and effective long-term therapy, Gastroenterology, 137, 10.1053/j.gastro.2009.07.043 · DOI
  161. Halilbasic, 2009, Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2−/− mice, Hepatology, 49, 1972, 10.1002/hep.22891 · DOI
  162. Hofmann, 2005, Novel biotransformation and physiological properties of norursodeoxycholic acid in humans, Hepatology, 42, 1391, 10.1002/hep.20943 · DOI
  163. Hofmann, 2009, Bile acids: trying to understand their chemistry and biology with the hope of helping patients, Hepatology, 49, 1403, 10.1002/hep.22789 · DOI · Paper page
  164. Yoon, 1986, Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents, Gastroenterology, 90, 837, 10.1016/0016-5085(86)90859-0 · DOI · Paper page
  165. Cipriani, 2009, FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats, J Lipid Res
  166. Fiorucci, 2005, Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis, J Pharmacol Exp Ther, 313, 604, 10.1124/jpet.104.079665 · DOI · Paper page
  167. Wang, 2009, Farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria, Am J Physiol Renal Physiol, 10.1152/ajprenal.00404.2009 · DOI · Paper page

Cited by

See all 162

Metadata

Authors
Maillette de Buy Wenniger, L., & Beuers, U.
Venue
Digestive and Liver Disease
Publisher
Elsevier BV
Published
2010-06
Volume
42
Issue
6
Pages
409-418
ISSN
1590-8658 (ISSN-L)
OpenAlex
W2133074258
Cited by
162
References
23
FWCI
4.70
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bile salts and cholestasis. https://app.cochat.ai/papers/10.1016/j.dld.2010.03.015
The paper
Maillette de Buy Wenniger, L., & Beuers, U. (2010). Bile salts and cholestasis. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2010.03.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.